13 November 2026
5
min read
Hemolytic Anemia Induced by Chronic Nitrofurantoin Use: Case Report and Review of the Literature
A case report highlighting Coombs-negative hemolytic anemia induced by chronic nitrofurantoin prophylaxis in a 90-year-old patient, demonstrating full hematologic recovery following drug withdrawal.
A case report highlighting Coombs-negative hemolytic anemia induced by chronic nitrofurantoin prophylaxis in a 90-year-old patient, demonstrating full hematologic recovery following drug withdrawal.

Updated:
13 November 2026
ABSTRACT
Nitrofurantoin is an antimicrobial commonly used to treat urinary tract infections and for their prophylaxis. Despite its relative safety, prolonged use can result in serious adverse effects, including hemolytic anemia. We describe the case of a 90-year-old woman with neurological sequelae from a stroke and neurogenic bladder who developed hemolytic anemia secondary to prolonged use of nitrofurantoin. The case highlights the diagnostic challenge, the importance of clinical-laboratory correlation, and the resolution after discontinuation of the medication.
Keywords: nitrofurantoin, hemolytic anemia, drug-induced hemolysis, elderly,
1. INTRODUCTION
Nitrofurantoin is a nitrofuran-derived antibiotic frequently prescribed for the prophylaxis of recurrent urinary tract infections, particularly in elderly patients with neurogenic bladder or chronic catheterization. Although considered safe, long-term exposure can lead to pulmonary, hepatic, and hematological toxicities, including immune and non-immune hemolytic anemia [1–4].
Recognition of these adverse events is essential, especially in frail elderly individuals, as symptoms may be nonspecific and attributed to comorbidities. This case report describes a case of hemolytic anemia induced by chronic nitrofurantoin use and reviews the main diagnostic and treatment considerations.
2. CASE PRESENTATION
2.1 Patient information
A 90-year-old female patient with neurological sequelae from an ischemic stroke, essential hypertension, unspecified arrhythmia, fibromyalgia, and neurogenic bladder, continuously using a Foley catheter.
She was in a home care program and had been using nitrofurantoin 100 mg/day for prophylaxis of recurrent urinary tract infection for at least 3 months before July 2025, the month in which the author began assisting her with monthly medical visits.
2.2 Clinical history and initial evaluation
Between July and August 2025, the patient developed a clinical picture consistent with arthritis in the metacarpophalangeal joints of the 3rd and 4th right fingers. Treatment with a non-steroidal anti-inflammatory drug was prescribed, which led to complete improvement of the condition. However, the condition worsened a few days after the end of the anti-inflammatory treatment.
During the monthly home medical visit in August 2025, laboratory tests were requested due to the clinical impression of rheumatoid arthritis, including a complete blood count, inflammatory markers, and an autoimmunity panel. Despite being pale, the patient was hemodynamically and ventilator-wise stable during her medical visit.
Laboratory tests revealed unexpected results. The complete blood count showed anemia with marked poikilocytosis and schistocytes, suggesting a hemolytic process. At the same time, the ANA test was weakly positive. Throughout the period, the patient remained hemodynamically and ventilator-wise stable, and afebrile.
Given her chronic use of nitrofurantoin and the exclusive and non-significant elevation of ANA, drug-induced hemolytic anemia was suspected, and the medication was immediately discontinued on August 23, 2025.
2.3 Laboratory Findings
2.3.1 Initial tests (August 21, 2025)
The patient's initial data is presented in Table 1. We can observe hemolytic anemia, likely drug-induced, with negative direct antiglobulin test (nonimmune mechanism possible).
Table 1- Initial Laboratory Findings
Parameter | Result | Reference | Interpretation |
Hemoglobin | 5.9 g/dl | 11.5-164 g/dl | ↓↓ |
Hematocrit | 17.9% | 37-47% | ↓↓ |
RBC count | 2.65 M/mm³ | 3.8 – 5.8 M/mm³ | ↓ |
RDW | 18.7% | 11.6 – 14.6% | ↑ |
Reticulocytes | 0.9 % | 0.5–2.0% | ↓–normal |
Coombs test | negative | negative | normal |
ESR | 29 mm/h | <20 mm/h | ↑ mild |
Schistocytes, codocytes, elliptocytes | Present | Absent | Suggest hemolysis |
CRP | 21 mg/L | <5 mg/L | ↑ |
Rheumatoid factor | 10 IU/mL | 14 IU/mL | Normal |
ANA | 1:80 nucleolar homogeneous | Negative | Weak positive (nonspecific) |
LDH | 293 U/L | <250 U/L | Mild ↑ |
Total bilirubin | 2.17 mg/dL (indirect 1.86) | <1.2 mg/dL | ↑ |
Haptoglobin | 239 mg/dL | 30–200 mg/dL | Near-normal |
Creatinine | 0.6 mg/dL | 0.5–0.9 mg/dL | Normal |
Source: Prepared by the authors (2025).
2.3.2. Final laboratory findings (September 11,2025 – 15 days after drug withdrawal)
The patient's final data is presented in Table 2. We can observe gradual hematologic recovery following nitrofurantoin cessation, supporting causality.
Table 2 - Follow-up laboratory data
Parameter | Result | Reference | Change |
Hemoglobin | 7.8 g/dL | 11.5–16.4 g/dL | ↑ improvement |
Hematocrit | 23.9 % | 37–47% | ↑ |
RBC count | 2.87 M/mm³ | 3.8–5.8 M/mm³ | ↑ |
Reticulocytes | 1.2 % | 0.5–2.0% | Normal |
Coombs test | Negative | Negative | Normal |
RBC morphology | Poiquilocytosis, codocytes | Negative | persisting but improving |
Source: Prepared by the author (2025).
Table 3 - Timeline of Key Events
Date | Event | Main Interventions | Findings |
≥ Jul 2025 | On nitrofurantoin 100 mg/day | For urinary tract infection prophylaxis | None |
Aug 2025 | Onset of arthritis symptoms | Labs ordered for rheumatic evaluation | None |
21 Aug 2025 | Initial labs | None | Hb 5.9 g/dL, schistocytes, bilirubin↑ |
23 Aug 2025 | None | Nitrofurantoin discontinued | None |
11 Sep 2025 | Follow-up labs | Nitrofurantoin discotinued | Hb 7.8 g/dL, reticulocytes 1.2 %, Coombs - / no transfusion required |
3. DISCUSSION
Nitrofurantoin-induced hemolytic anemia is rare but well documented, occurring via oxidative injury to erythrocytes or, less frequently, immune-mediated hemolysis.
The direct antiglobulin test may be negative in oxidative hemolysis, as seen here, distinguishing it from autoimmune hemolytic anemia [5–7].
This patient’s presentation was insidious and detected only through routine labs requested for unrelated arthritis. The absence of fever or jaundice initially masked the etiology, emphasizing the need for vigilance in elderly patients under chronic nitrofurantoin therapy.
In this case, laboratory data supported a nonimmune hemolytic process:
Normocytic normochromic anemia with schistocytes
Elevated indirect bilirubin and LDH
Absence of marrow suppression or renal dysfunction
Recovery after drug discontinuation without other interventions.
The hemoglobin increase from 5.9 g/dL to 7.8 g/dL within two weeks confirmed clinical improvement. The normal reticulocyte count reflects a recovering marrow after transient suppression due to oxidative stress.
No transfusion or corticosteroid therapy was required, consistent with benign and self-limiting cases reported in the literature [8–10].
4. CONCLUSION
This case illustrates that chronic exposure to nitrofurantoin can cause hemolytic anemia even in the absence of G6PD deficiency or immunopositivity. In elderly patients, routine monitoring of complete blood counts is essential when the drug is used for long-term prophylaxis.
In all documented cases, immediate recognition and discontinuation of the drug lead to complete hematological recovery.
5. PATIENT PERSPECTIVE
The patient’s family reported progressive improvement in strength and vitality after the medication was stopped, with no recurrence of urinary infections over the following month.
6. CARE CHECKLIST COMPLIANCE
This case adheres to the CARE Guidelines for case report completeness. Written consent was obtained from the patient’s family for academic publication in anonymized form.
7. REFERENCES
Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. Ann Pharmacother. 2013;47(1):106–111.
Holmberg L, Boman G, Böttiger LE. Adverse reactions to nitrofurantoin. Br Med J. 1967;4:73–75.
Phan M, et al. Nitrofurantoin-induced hemolytic anemia in elderly patients: a rare but serious adverse reaction. J Clin Pharm Ther. 2020;45(4):906–909.
Singh A, et al. Nitrofurantoin-related oxidative hemolysis without G6PD deficiency: a case report. Cureus. 2022;14(9):e29244.
Garratty G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009;2009(1):73–79.
Arndt PA, Garratty G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005;42(3):137–144.
Luzzatto L, Arese P. Favism and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med. 2018;378:60–71.
Ribeiro E, et al. Nitrofurantoin-induced hemolytic anemia: case report and literature review. Rev Bras Hematol Hemoter. 2015;37(6):422–425.
Schattner A, et al. Nitrofurantoin-induced autoimmune hemolytic anemia: report of two cases. Clin Pharmacol Ther. 2001;70(5):420–425.
Behera SK, et al. Nitrofurantoin-induced oxidative hemolysis in the elderly: case series and review. Indian J Hematol Blood Transfus. 2021;37(2):357–361.





Our Authors

Get the Latest Healthcare
Stories in Your Inbox.
Subscribe to our newsletter to receive new articles, case insights, and thought leadership from clinicians and researchers worldwide.
.png)